Journal Article

Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)

Maturu, Venkata Nagarjuna, Khanna, Arjun, Gadola, Stephan D., Keppler, Oliver T., Gilbert, Laura, Dhar, Raja, Djukanovic, Ratko, Modi, Mahavir Madhavdas, Chawla, Rakesh K., Stern, Marcel, Kirkpatrick, John, Dalal, Sonia

2023

Overview

After admission to hospital, COVID-19 progresses in a substantial proportion of patients to critical disease that requires intensive care unit (ICU) admission. In a pragmatic, non-blinded trial, 387 patients aged 40-90 years were randomised to receive treatment with SoC plus doxycycline (n = 192) or SoC only (n = 195). The primary outcome was the need for ICU admission as judged by the attending physicians. Three types of analyses were carried out for the primary outcome: \"Intention to treat\" (ITT) based on randomisation; \"Per protocol\" (PP), excluding patients not treated according to randomisation; and \"As treated\" (AT), based on actual treatment received. The trial was undertaken in six hospitals in India with high-quality ICU facilities. An online application serving as the electronic case report form was developed to enable screening, randomisation and collection of outcomes data. Adherence to treatment per protocol was 95.1%. Among all 387 participants, 77 (19.9%) developed critical disease needing ICU admission. In all three primary outcome analyses, doxycycline was associated with a relative risk reduction (RRR) and absolute risk reduction (ARR): ITT 31.6% RRR, 7.4% ARR (P = 0.063); PP 40.7% RRR, 9.6% ARR (P = 0.017); AT 43.2% RRR, 10.8% ARR (P = 0.007), with numbers needed to treat (NTT) of 13.4 (ITT), 10.4 (PP), and 9.3 (AT), respectively. Doxycycline was well tolerated with not a single patient stopping treatment due to adverse events. In hospitalized COVID-19 patients, doxycycline, a safe, inexpensive, and widely available antibiotic with anti-inflammatory properties, reduces the need for ICU admission when added to SoC.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Anti-inflammatory agents / Antibiotics / Antiviral drugs / Biology and Life Sciences / Case reports / Clinical trials / Coronaviruses / COVID-19 / Data collection / Doxycycline / Health risks / Health services / Hospitalization / Hospitals / Humans / Inflammation / Intensive care / Intensive Care Units / Medicine and Health Sciences / Pandemics / Patients / People and Places / Physicians / Pneumonia / Randomization / Risk management / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Treatment Outcome